Lilly pours more money into genetic treatments for neurological diseases
Bio Pharma Dive
JANUARY 6, 2022
For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.
Let's personalize your content